The Onset of Intussusceptive Angiogenesis in COVID-19 Patients Might Come from the Mobilization of Stem Cell Sub-Populations Expressing the Hemangioblast Marker CD143.

CD143 COVID-19 Hemangioblast Stem cells UN-SDG3

Journal

Stem cell reviews and reports
ISSN: 2629-3277
Titre abrégé: Stem Cell Rev Rep
Pays: United States
ID NLM: 101752767

Informations de publication

Date de publication:
09 May 2024
Historique:
accepted: 10 04 2024
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). The SARS-CoV-2 pandemic has unveiled complex pathophysiological mechanisms underpinning COVID-19, notably inducing a systemic acquired vascular hemopathy characterized by endothelial dysfunction and intussusceptive angiogenesis, a rapid vascular remodeling process identified as a hallmark in severe COVID-19 cases affecting pulmonary and cardiac tissues. Stem cell migration have been proposed as significant regulators of this neoangiogenic process. In a monocentric cross-sectional study, through spectral flow cytometry analysis of peripheral blood mononuclear cells, we identified a distinct stem cell subpopulation mobilized in critical COVID-19. Indeed, by an unsupervised analysis generating a UMAP representation we highlighted eleven different clusters in critical and non-critical COVID-19 patients. Only one cluster was significantly associated to critical COVID-19 compared to non-critical patients. This cluster expressed the markers: CD45dim, CD34+, CD117+, CD147+, and CD143+, and were negative for CD133. Higher level of expression of hemangioblast markers CD143 were found in critical COVID-19 patients. This population, indicative of hemangioblast-like cells, suggests a key role in COVID-19-related neoangiogenesis, potentially driving the severe vascular complications observed. Our findings underscore the need for further investigation into the contributions of adult stem cells in COVID-19 pathology, offering new insights into therapeutic targets and interventions.

Identifiants

pubmed: 38722523
doi: 10.1007/s12015-024-10727-1
pii: 10.1007/s12015-024-10727-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence nationale pour la recherche
ID : SARCODO

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Debuc, B., & Smadja, D. M. (2021). Is COVID-19 a New Hematologic Disease? Stem Cell Rev Rep, 17(1), 4–8.
doi: 10.1007/s12015-020-09987-4 pubmed: 32399806
Smadja, D. M., Mentzer, S. J., Fontenay, M., Laffan, M. A., Ackermann, M., Helms, J., et al. (2021). COVID-19 is a systemic vascular hemopathy: Insight for mechanistic and clinical aspects. Angiogenesis, 24(4), 755–788.
doi: 10.1007/s10456-021-09805-6 pubmed: 34184164
Smadja, D. M., Jannot, A. S., Philippe, A., Lu, E., Rancic, J., Sanchez, O. (2023). Circulating Von Willebrand factor: A consistent biomarker predicting in-hospital mortality across different waves of the COVID-19 pandemic. Angiogenesis. .
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al. (2020). Pulmonary vascular endothelialitis, thrombosis, and Angiogenesis in Covid-19. New England Journal of Medicine, 383(2), 120–128.
doi: 10.1056/NEJMoa2015432 pubmed: 32437596
Werlein, C., Ackermann, M., Stark, H., Shah, H. R., Tzankov, A., Haslbauer, J. D. (2022). Inflammation and vascular remodeling in COVID-19 hearts. Angiogenesis. ;1–16.
Djonov, V., Schmid, M., Tschanz, S. A., & Burri, P. H. (2000). Intussusceptive Angiogenesis: Its role in embryonic vascular network formation. Circulation Research, 86(3), 286–292.
doi: 10.1161/01.RES.86.3.286 pubmed: 10679480
Baum, O., Suter, F., Gerber, B., Tschanz, S. A., Buergy, R., Blank, F., et al. (2010). VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane. Microcirculation (New York, N.Y. : 1994), 17(6), 447–457.
pubmed: 20690983
Philippe, A., Günther, S., Rancic, J., Cavagna, P., Renaud, B., Gendron, N. (2023). VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients. Angiogenesis. .
Guerin, C. L., Guyonnet, L., Goudot, G., Revets, D., Konstantinou, M., Chipont, A., et al. (2021). Multidimensional Proteomic Approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 cells. Stem Cell Rev Rep, 17(2), 639–651.
doi: 10.1007/s12015-020-10062-1 pubmed: 33205351
Philippe, A., Chocron, R., Gendron, N., Bory, O., Beauvais, A., Peron, N., et al. (2021). Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 24(3), 505–517.
doi: 10.1007/s10456-020-09762-6 pubmed: 33449299
Smadja, D. M., Philippe, A., Ferreira, E. V. M., Oliveira, R. K. F., McCabe, C., & Zhao, L. (2023). CD147 plasma levels in Hospitalised patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital mortality. Stem Cell Rev Rep. .
Ulrich, H., & Pillat, M. M. (2020). CD147 as a target for COVID-19 treatment: Suggested effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep, 16(3), 434–440.
doi: 10.1007/s12015-020-09976-7 pubmed: 32307653
Geng, J., Chen, L., Yuan, Y., Wang, K., Wang, Y., Qin, C., et al. (2021). CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Sig Transduct Target Ther, 6(1), 347.
doi: 10.1038/s41392-021-00760-8
Zambidis, E. T., Park, T. S., Yu, W., Tam, A., Levine, M., Yuan, X., et al. (2008). Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 112(9), 3601–3614.
doi: 10.1182/blood-2008-03-144766 pubmed: 18728246
Rodgers, K. E., & Dizerega, G. S. (2013). Contribution of the local RAS to hematopoietic function: A Novel Therapeutic Target. Front Endocrinol (Lausanne), 4, 157.
doi: 10.3389/fendo.2013.00157 pubmed: 24167502
Slukvin, I. I. (2009). Renin-angiotensin system and hemangioblast development from human embryonic stem cells. Expert Rev Hematol, 2(2), 137–143.
doi: 10.1586/ehm.09.4 pubmed: 21083448
Becht, E., McInnes, L., Healy, J., Dutertre, C. A., Kwok, I. W. H., Ng, L. G. (2018). Dimensionality reduction for visualizing single-cell data using UMAP. Nature Biotechnology. .
Aragon, J. W., & Hirschi, K. K. (2022). Endothelial cell differentiation and hemogenic specification. Cold Spring Harb Perspect Med, 12(7), a041164.
doi: 10.1101/cshperspect.a041164 pubmed: 35193895
Ratajczak, M. Z. (2015). A novel view of the adult bone marrow stem cell hierarchy and stem cell trafficking. Leukemia, 29(4), 776–782.
doi: 10.1038/leu.2014.346 pubmed: 25486871
Ratajczak, M. Z., Ratajczak, J., & Kucia, M. (2019). Very small embryonic-like Stem cells (VSELs). Circ Res, 124(2), 208–210.
doi: 10.1161/CIRCRESAHA.118.314287 pubmed: 30653438
Smadja, D. M., Melero-Martin, J. M., Eikenboom, J., Bowman, M., Sabatier, F., & Randi, A. M. (2019). Standardization of methods to quantify and culture endothelial colony-forming cells derived from peripheral blood: Position paper from the International Society on thrombosis and haemostasis SSC. Journal of Thrombosis and Haemostasis, 17(7), 1190–1194.
doi: 10.1111/jth.14462 pubmed: 31119878
Blandinieres, A., Randi, A. M., Paschalaki, K. E., Guerin, C. L., Melero-Martin, J. M., & Smadja, D. M. (2023). Results of an international survey about methods used to isolate human endothelial colony-forming cells (ECFCs): Guidance from the Scientific and Standardization Committee on Vascular Biology of the International Society of Thrombosis and hemostasis. J Thromb Haemost. ;S1538-7836(23)00498-1.
Sherman, S. E., Kuljanin, M., Cooper, T. T., Lajoie, G. A., & Hess, D. A. (2020). Purification and functional characterization of CD34-Expressing cell subsets following Ex vivo expansion of umbilical cord blood-derived endothelial colony-forming cells. Stem Cells and Development, 29(14), 895–910.
doi: 10.1089/scd.2020.0008 pubmed: 32336222

Auteurs

Lou Soret (L)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France.
Hematology Department, AP-HP, Saint louis Hospital, Paris, F-75010, France.

Coralie L Guerin (CL)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France.
Cytometry Platform, Curie CoreTech, Institut Curie, Paris, F-75005, France.

Guillaume Goudot (G)

Université Paris-Cité, PARCC, INSERM, Paris, F-75015, France.
Vascular medicine Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France.

Léa Guyonnet (L)

Cytometry Platform, Curie CoreTech, Institut Curie, Paris, F-75005, France.

Jean-Luc Diehl (JL)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France.
Intensive Care Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France.

Aurélien Philippe (A)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France.
Hematology Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France.

Pascale Gaussem (P)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France.
Hematology Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France.

David M Smadja (DM)

Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, Paris, F-75006, France. david.smadja@me.com.
Hematology Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France. david.smadja@me.com.
Innovative Therapies in Hemostasis, Hematology Department in Georges Pompidou, Paris-Cité University, INSERM, European Hospital, 20 rue Leblanc, 75015, Paris, France. david.smadja@me.com.

Classifications MeSH